Mahadi Baig: U.S. FDA granted priority review of Johnson and Johnson Innovative Medicine’s subcutaneous treatment for patients with EGFR-mutated NSCLC

Mahadi Baig, Global Medical Head, Amivantamab at Johnson and Johnson, shared a post on LinkedIn:

“I’m pleased to announce that today, the U.S. FDA granted priority review of Johnson and  Johnson Innovative Medicine’s application for a subcutaneous treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC).

This treatment, with its potential to transform the treatment experience for patients, clearly demonstrates our team’s unwavering commitment to a ‘patient-centric‘ approach to developing better therapies.

I am incredibly proud of this team as we continue to put patients at the forefront of everything we do.

Learn more about the submission.”

Source: Mahadi Baig/LinkedIn